In the past, metal-based compounds were widely used in the treatment of disease
conditions, but the lack of clear distinction between the therapeutic and toxic doses was a …

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

History shows that metal-based drugs and remedies have been known and used since very
ancient times. For example, silver was employed in the treatment of wounds and ulcers …

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of
the metal, its oxidation state, the types and number of coordinated ligands and the …

This review provides an introduction into the fascinating area of organometallic anticancer
compounds. Although the subject dates back many years, it has witnessed considerable …

Interest in the medicinal properties of ruthenium (II)–arene compounds has grown rapidly
over the last decade. In this account we describe the origins of the field and subsequently …

The antimetastatic ruthenium (II) compounds [Ru (η6-p-cymene) Cl2 (PTA)](PTA= 1, 3, 5-
triaza-7-phosphaadamantane)(RAPTA-C) and [Ru (η6-toluene) Cl2 (PTA)](RAPTA-T), as …

Metallodrugs have a central role in the treatment and diagnosis of diseases. To overcome
potential toxicity and equip metal-based anticancer agents with biological activity, the choice …

Highlights•Osmium complexes are promising anticancer agents.•In vitro assays revealed
antiproliferative activity in nanomolar concentrations.•New leads of osmium are well …

The synthesis of four novel heteroleptic dipyrrinato complexes [(η6-arene) RuCl (2-
pcdpm)](η6-arene= C6H6, 1; C10H14, 2) and [(η5-C5Me5) MCl (2-pcdpm)](M= Rh, 3; Ir, 4) …